Event Overview:
Finding ways to improve the solubility and bioavailability of poorly soluble drugs is of crucial importance to pharmaceutical companies. Industry estimates indicate that approximately 40% of commercial drugs and 60% of drugs under development may be considered poorly soluble. Pharmaceutical development scientists face the challenge of developing formulations and processes for poorly soluble drugs with minimal time for experimental work and limited supply of expensive new chemical entities (NCEs). This 60-min Webcast will offer insight from leading industry experts on solid-dispersion technologies used to enhance solubility when formulating poorly soluble drugs. Gain insight into how melt extrusion is used in the pharmaceutical industry and of a systematic approach for initial feasibility development of formulation and processes involving pharmaceutical melt extrusion. This approach, Melt Extrusion Modeling & Formulation Information System (MEMFIS), helps in selecting lead formulations with no API consumption, using mathematical models and algorithms based on solubility parameter theories (i.e. hydrogen bonding, polar and dispersive forces), which ensure the stabilization of the system through hydrogen bonding.

---

Key Learning Objectives:
To provide an in-depth understanding of pharmaceutical melt extrusion To demonstrate the effective use of pharmaceutical melt extrusion for solubility enhancement of poorly water soluble APIs. To demonstrate the use of current methodology for pharmaceutical melt extrusion and process development.

---

Who Should Attend: Those responsible or involved with oral solid formulation development, including:
»	Formulation scientists
»	Formulation R&D managers, directors, and group leaders
»	Production managers
»	Quality control and quality assurance directors
»	Marketing managers
»	Section heads
»	Project managers
»	Academic researchers

---

	Moderator: Uwe Weidenauer, Ph.D. Director, Strategic Projects Pharma Polymers Evonik Röhm GmbH		Sponsored by:
	Presenter: Navnit H. Shah, Ph.D. Distinguished Research Leader Hoffmann-La Roche, Inc.		Presenter: Firouz Asgarzadeh, Ph.D. Principal Scientist Pharma Polymers Evonik Degussa Corporation